(Q34360536)

1 August 2017

1 reference

title

Immunotherapy of insulin-dependent diabetes mellitus. (English)

1 reference

1 August 2017

1 reference

1 reference

Bach JF

1

1 reference

1 August 2017

1 October 2001

1 reference

Current Opinion in Immunology

1 August 2017

1 reference

1 August 2017

13

1 reference

1 August 2017

601-605

1 reference

1 August 2017

5

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Peptide therapy for diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Tolerance to islet autoantigens in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

DNA immunization to prevent autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Induction of Autoimmune Diabetes by Oral Administration of Autoantigen

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting their destruction of pancreatic beta cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

The involvement of Ly 2+ T cells in beta cell destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Prevention of diabetes mellitus in the non-obese diabetic mouse strain with monoclonal antibodies against the CD45RB molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Anti-α/β T cell receptor monoclonal antibody provides an efficient therapy for autoimmune diabetes in nonobese diabetic (NOD) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Regulatory T cells: key controllers of immunologic self-tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

PHASE I STUDY OF AN ENGINEERED AGLYCOSYLATED HUMANIZED CD3 ANTIBODY IN RENAL TRANSPLANT REJECTION1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Regulatory T cells and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

CTLA-4 up-regulation plays a role in tolerance mediated by CD45.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Biolistic-mediated interleukin 4 gene transfer prevents the onset of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

T-cell production of an inducible interleukin-10 transgene provides limited protection from autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543)

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Protective role of infections and vaccinations on autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Altered cytokine activity in adjuvant inhibition of autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Mechanisms of Mycobacterium avium-induced resistance against insulin-dependent diabetes mellitus (IDDM) in non-obese diabetic (NOD) mice: role of Fas and Th1 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900267-3

7 January 2021

10.1016/S0952-7915(00)00267-3

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11544012